Pulmonary Cell News Volume 4.41 | Oct 22 2015

Bombesin Receptor-Activated Protein (BRAP) Modulates NF-κB Activation in Bronchial Epithelial Cells by Enhancing HDAC Activity
The authors demonstrated that BRAP has a regulatory effect on NF-κB transcriptional activity in cultured human bronchial epithelial cells (HBECs). BRAP overexpression by gene transfer inhibited both basal and inducible NF-κB transcriptional activity in HBECs, whereas BRAP knockdown had the opposite effect. [J Cell Biochem] Abstract

Normal and Cystic Fibrosis Human Bronchial Epithelial Cells Infected with Pseudomonas aeruginosa Exhibit Distinct Gene Activation Patterns
To identify the molecular determinants of an effective response to P. aeruginosa infection, scientists performed a transcriptomic analysis of primary human bronchial epithelial cells from healthy donors two, four, and six hours after induced P. aeruginosa infection. [PLoS One] Full Article

Anti-Inflammatory Effects of Resveratrol on Hypoxia/Reoxygenation–Induced Alveolar Epithelial Cell Dysfunction
The authors demonstrated resveratrol-mediated reversal of hypoxia-reoxygenation-induced inflammatory responses and dysfunction of type II pneumocyte cells in vitro. [J Agric Food Chem]
Abstract | Graphical Abstract

LUNG CANCER

pH Sensitive Nano Layered Double Hydroxides Reduce the Hematotoxicity and Enhance the Anticancer Efficacy of Etoposide on Non-Small Cell Lung Cancer
The functions of layered double hydroxides (LDH) carrying etoposide (VP16) on non-small cell lung cancer were explored both in vitro and in vivo. In A549 cell line, LDH-VP16 induced apoptosis 2.3-fold as that of plain VP16 by targeting to mitochondrial, stocking cells in G1 phase. [Acta Biomater] Abstract

miR-342-3p Regulates MYC Transcriptional Activity via Direct Repression of E2F1 in Human Lung Cancer
The authors attempted to identify miRNAs involved in regulation of MYC transcriptional activity in lung cancer. To this end, they utilized an integrative approach with combinatorial usage of miRNA and mRNA expression profile datasets of patient tumor tissues, as well as those of MYC-inducible cell lines in vitro. [Carcinogenesis] Abstract

Role of miR-497 in VEGF-A-Mediated Cancer Cell Growth and Invasion in Non-Small Cell Lung Cancer
Researchers showed that compared to other cancers, non-small cell lung cancer (NSCLC) had a significant higher ratio of vascular endothelial growth factor A (VEGF-A) protein vs mRNA, and significantly lower levels of miR-497, suggesting presence of a post-transcriptional control of VEGF-A in NSCLC different from other cancers. [Int J Biochem Cell Biol] Abstract

c-Myc-Regulated Long Non-Coding RNA H19 Indicates a Poor Prognosis and Affects Cell Proliferation in Non-Small-Cell Lung Cancer
Researchers assessed the biological role of long non-coding RNA H19 in non-small-cell lung cancer (NSCLC). Knockdown of H19 significantly inhibited NSCLC cell proliferation both in vitro and in vivo. [Tumor Biol] Abstract

The Regulatory and Predictive Functions of miR-17 and miR-92 Families on Cisplatin Resistance of Non-Small Cell Lung Cancer
Abnormal expressions of miR-17 and miR-92 families were observed in cisplatin-resistant cells, suggesting that miR-17 and miR-92 families are involved in the regulation of cisplatin resistance in non-small cell lung cancer. [BMC Cancer] Full Article

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

UofL Researchers Awarded Patents for Innovations to Improve Cancer Treatments, Bone Grafts and Therapies for Spinal Cord Damage
Technologies to improve bone grafts and cancer immunotherapies, protect lung tissue during radiation treatment, reverse neurological damage and improve recovery from spinal cord injury are among the patents issued to the University of Louisville (UofL) Research Foundation recently. [University of Louisville School of Medicine] Press Release

Southern Research Receives $7.5 Million Award to Discover New Therapies for Cystic Fibrosis Patients with Rare Mutations
Southern Research has received an award from the Cystic Fibrosis Foundation’s nonprofit drug discovery and development affiliate, Cystic Fibrosis Foundation Therapeutics, Inc. The funding will support research focused on the development of novel drugs for cystic fibrosis (CF) patients with rare genetic mutations, furthering the ultimate goal of treating all people with CF. [Southern Research] Press Release

Synta Announces Termination for Futility of Ganetespib Phase III GALAXY-2 Trial in Lung Cancer
Synta Pharmaceuticals Corp. announced that the company has decided to terminate the Phase III GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma. [Synta Pharmaceuticals Corp.] Press Release

From our sponsor:
Want to learn more about ALDH in breast cancer treatment response? Listen to the podcast.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pulmonary cell community.

NEW Postdoctoral Position – Lung Biology Research (University of Southern California)

NEW Postdoctoral Fellowship – Developmental Cell Biology and Regenerative Medicine (University of California San Francisco)

Postdoctoral Researcher – Molecular Mechanisms of Pulmonary Diseases (Eastern Virginia Medical School)

Clinical Research Fellow – Small Cell Lung Cancer (Cancer Research UK Manchester Institute)

Postdoctoral Fellow – Asthma (The University of Tennessee Health Science Center)

Postdoctoral Scholar – Autoimmune Diseases Affecting the Lung (University of California, San Francisco)

Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Postdoctoral Research Fellow – Small Cell Lung Cancer (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.